ChemicalBook > Product Catalog >Biochemical Engineering >Inhibitors >EC330

EC330

EC330 Suppliers list
Company Name: ATK CHEMICAL COMPANY LIMITED
Tel: +undefined-21-51877795
Email: ivan@atkchemical.com
Products Intro: Product Name:(EC330)
CAS:2016795-77-8
Purity:98% Package:10MG;50MG;100MG,1G,5G,10G.100G
Company Name: BOC Sciences
Tel: +1-631-485-4226
Email: inquiry@bocsci.com
Products Intro: Product Name:EC330
CAS:2016795-77-8
Package:5mg Remarks:BOC Sciences also provides custom synthesis services for EC330.
Company Name: Career Henan Chemica Co
Tel: +86-0371-86658258 15093356674;
Email: laboratory@coreychem.com
Products Intro: Product Name:;Estra-4,9-dien-3-one, 11-(4-cyclopropylphenyl)-17-(1,1-difluoro-2-propyn-1-yl)-17-hydroxy-, (11β,17β)-
CAS:2016795-77-8
Purity:85.0-99.8% Package:1ASSAYS;1USD
Company Name: Shanghai Gubang New Materail Technology Co. LTD
Tel: 21-51317962 +8618721305404
Email: 16728589@qq.com
Products Intro: CAS:2016795-77-8
Package:1 g 2 g, 5 g, 10 g, 1000 g
Company Name: InvivoChem
Tel: +1-708-310-1919 +1-13798911105
Email: sales@invivochem.cn
Products Intro: Product Name:EC330
CAS:2016795-77-8
Purity:98% Package:5mg Remarks:V31917
EC330 Basic information
Product Name:EC330
Synonyms:EC330;Estra-4,9-dien-3-one, 11-(4-cyclopropylphenyl)-17-(1,1-difluoro-2-propyn-1-yl)-17-hydroxy-, (11β,17β)-;EC-330; EC 330;EC-330,EC 330,EC330,inhibit,Inhibitor;(8S,11R,13S,14S,17S)-11-(4-Cyclopropylphenyl)-17-(1,1-difluoroprop-2-yn-1-yl)-17-hydroxy-13-methyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one
CAS:2016795-77-8
MF:C30H32F2O2
MW:462.57
EINECS:
Product Categories:
Mol File:2016795-77-8.mol
EC330 Structure
EC330 Chemical Properties
Boiling point 623.4±55.0 °C(Predicted)
density 1.26±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMSO : 20 mg/mL (43.24 mM)
pka12.90±0.60(Predicted)
Safety Information
HS Code 2914409000
MSDS Information
EC330 Usage And Synthesis
DescriptionEC330 is used as potential LIF inhibitors. The remaining EC330-like inhibitors include EC357, and EC363. They were designed based on the structure–activity relationship (SAR) studies on human breast cancer MCF7 cells with LIF overexpression. The SAR established through this screening includes following criteria: (i) the steroidal skeleton of the molecule is an antiprogestin, (ii) the molecule has the specific 17α-difluoro acetylenic moiety, and (iii) nonpolar substituents at position 11 are preferred over polar substituents. EC330, EC357, and EC363 have all these features. EC330 inhibits the LIF/LIF-R signaling and blocks the promoting effects of LIF on growth and migration of cancer cells.[1].
in vitroEC330 shows marked specificity in MCF-7 cells overexpressing LIF verses MCF-7 cells. EC330 further shows cytoskeletal disruption and targeting cancer-associated fibroblasts (CAFs) through inhibition of alpha-SMA but not beta-tubulin.
in vivoEC330 treatment (0.1, 0.5 and 2.5 mg/kg) dose dependently reduces tumor burden in ovarian (IGROV-1) and triple negative breast cancer (MDA-MB-231) cell xenografted mouse models as well as MDA-MB-231 PDX models. EC330 exhibits no reactivity towards thiol-cysteine residues, no off target binding to major receptors, kinases or ion channels. EC330 is orally bioavailable and found to be safe and tolerable in toxicity studies.
EC330 Preparation Products And Raw materials
Tag:EC330(2016795-77-8) Related Product Information